Proactive Investors - Run By Investors For Investors

Venn lands €3.4mln contract with US biotech

The contract research group, which provides clinical trial management and resourcing for the drugs industry, has struck the deal with an unnamed by leading US-based biotechnology client.
Venn lands €3.4mln contract with US biotech
Companies outsource clinical trials to Venn.

The current year is already shaping up to be a good one for Venn Life Sciences (LON:VENN), though the foundation work for today’s €3.4mln order was done in 2015, the company said.

The contract research group, which provides clinical trial management and resourcing for the drugs industry, has struck the deal with an unnamed by leading US-based biotechnology client.

The work is an extension to an existing phase II clinical trial, so it will start immediately and run to the end of 2017.

Venn chief Tony Richardson said: "During 2015, I commented that executing our work to a consistent high standard would bring significant rewards and I am delighted to be able to show the concrete evidence of this.

“This is the second extension of what is a complex international programme and this endorsement is well deserved by our team. It is particularly pleasing to win this business at the commencement of the new year. 2015 was a year of significant growth at Venn and new business wins of this magnitude will enable us to continue expanding our business."    

On Friday the company told investors that it expects revenues for 2015 to be at least double the prior year.

It highlighted that it has won enterprise level contracts and has grown its reputation for excellence.

Venn also said it ended December with €3.4mln of cash. The business was now generating free cash flows, and was well funded for future growth, it added.

View full VENN profile View Profile

Venn Life Sciences Holdings plc Timeline

March 22 2017
November 02 2016

Related Articles

numerous pills
March 23 2018
Genervon is on the lookout for pharma partners to help advance its GM6 drug, which takes aim at a range of deadly diseases hitting the central nervous system
April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible
profit meter
April 02 2018
Having secured US$6.9mln of new investment, the company is now primed for growth

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use